Global Biologics CDMO Market - A Global and Regional Analysis, 2023-2033

Nov 2023| BIS827A| BIS Research

Report Highlights

Global Biologics CDMO Market Set to Surge, Riding the Wave of Innovation and Demand

Biologics CDMO Industry Overview

The global biologics CDMO market was valued at $XX billion in 2022 and is anticipated to reach $XX billion by 2033, witnessing a CAGR of XX% during the forecast period 2023-2033.

Introduction to Biologics CDMO Market

The global biologics CDMO market plays a crucial role in the pharmaceutical and biotechnology industries, offering specialized services for the development, manufacturing, and testing of biologic drugs. Biologics are complex molecules derived from living organisms, such as proteins, antibodies, and nucleic acids, and they have become increasingly important in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases.

CDMOs in the biologics sector provide a range of services, including cell line development, process development, scale-up, manufacturing, quality control, and regulatory support. These organizations serve as strategic partners for pharmaceutical and biotech companies, allowing them to outsource certain aspects of the drug development and manufacturing process, thereby gaining efficiency, expertise, and flexibility.

Market Segmentation:

Segmentation 1: by Cell Type

  • Mammalian
  • Non-mammalian

Segmentation 2: by Product Type

  • Biologics
  • Monoclonal Antibodies
  • Recombinant Proteins
  • Antisense and Molecular Therapy
  • Vaccines
  • Other Biologics
  • Biosimilars

Segmentation 3: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • MEA

The report provides data for each of these regions, with in-depth country-level analyses, all covering the period from 2022 to 2033.

Report Synopsis

Report Metrics Details
Base year considered 2023
Forecast period considered 2023-2033
Units considered $ Billion
Segments covered By Cell Type, By Product Type, By Region
Industry covered BIS Healthcare
Regions covered North America, Europe, Middle East and Africa, Asia-Pacific, Latin America
Countries covered U.S., Canada, Germany, Italy, France, U.K., Spain, Rest-of-Europe, China, Japan, India, Australia, Rest-of-Asia-Pacific, Brazil, Mexico, Rest-of-Latin America, U.A.E., Saudi Arabia, Rest-of-Middle East and Africa
Companies studied
  • Boehringer Ingelheim Group
  • Toyobo Co. Limited
  • Lonza Group
  • Samsung Biologics
  • NOVARTIS AG
  • AGC Biologics
  • Parexel International Corporation
  • Catalent Inc.
  • Binex Co. Limited
  • AbbVie Contract Manufacturing

How can this report add value to an organization?

Product/Innovation Strategy: The global biologics CDMO market has been extensively segmented based on various categories, such as cell type and product type. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: The global biologics CDMO market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint venture.

Competitive Strategy: Key players in the global biologics CDMO market analyzed and profiled in the study involve established and emerging players. Moreover, a detailed competitive benchmarking of the players operating in the global biologics CDMO market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

  • Boehringer Ingelheim Group
  • Lonza Group
  • Samsung Biologics
  • NOVARTIS AG
  • Toyobo Co. Limited
  • Parexel International Corporation
  • Catalent Inc.
  • Binex Co. Limited
  • AGC Biologics
  • AbbVie Contract Manufacturing

This report will be delivered in 2-3 working days.

BIS Research is a global B2B market intelligence and advisory firm focusing on those emerging technological trends which are likely to disrupt the dynamics of the market.

With over 150 market research reports published annually, BIS Research focuses on high technology verticals such as 3D Printing, Advanced Materials and Chemicals, Aerospace and Defense, Automotive, Healthcare, Electronics and Semiconductors, Robotics and UAV, and other emerging technologies.

Our in-depth market intelligence reports focus on the market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

BIS Research
Price: $4950

Become a Member

Already a member? Login here.

Have a Question? Ask Us.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS